



EUROPEAN CHARCOT FOUNDATION

SYMPOSIUM 2005

PROGRAMME

Treatment Strategies in Multiple Sclerosis

from pathophysiology to clinical practice

November 17-18-19 November, 2005
Pestana Palace Hotel Lisbon, Portugal

11TH European Charcot Foundation Lecture

Prof. Ludwig Kappos

Developing new treatment options for people with Multiple Sclerosis.
A success story or Sisyphus' labour?

Thursday November 17, 2005

Thursday November 17, 2005

Afternoon session

Chairmen: **O.R. Hommes and G. Edan**

- 14.00 – 14.05 Opening
O.R. Hommes
- 14.05 – 15.00 11th European Charcot Foundation Lecture
L. Kappos
Developing new treatment options for people with Multiple Sclerosis.
A success story or Sisyphus' labour?
- 15.00 – 15.30 Discussion
- 15.30 – 16.00 Coffee

Pathophysiological clues for treatment

Chairmen: **H. Lassmann and H.P. Hartung**

- 16.00 – 16.15 Pathology in MS: mechanisms at different stages of disease evolution.
What precedes inflammation?
H. Lassmann
- 16.15 – 16.30 Inflammation and neurodegeneration in early MS
M. Filippi
- 16.30 – 16.45 Brain perfusion in MS. Is it caused by inflammation alone?
F. Zipp
- 16.45 – 17.00 Lessons from epidemiology for the pathological background of MS
G. Edan
- 17.00 – 17.15 Disease biomarkers as indicated by pathophysiology
T. Berger
- 17.15 – 17.30 Discussion
- 18.00 – 19.00 Welcome reception

Friday November 18, 2005

Morning session

Approved drugs and their problems in patient care

Chairmen: **P. Soelberg Sørensen and L. Kappos**

- 8.00 – 8.15 Pharmacodynamics and pharmacokinetics of glatirameracetate,
interferon beta's and mitoxantrone
H-P. Hartung
- 8.15 – 8.30 Routes of administration and dosing
S. Cook
- 8.30 – 8.45 Toxicity and side-effects of licensed MS disease-modifying therapies:
how to improve concordance
G. Giovannoni
- 8.45 – 9.00 Postmarketing investigations
X. Montalban
- 9.00 – 9.15 Discussion
- 9.15 – 9.45 Coffee

Friday November 18, 2005 (continued)

New-comers: promises and failures

Chairmen:	X. Montalban and K. Selmaj
9.45 – 10.00	Inflammation versus neurodegeneration: consequences for treatment J. Palace
10.00 – 10.15	Perspectives and risks of blocking inflammation (chemokines) R. Ransohoff
10.15 – 10.30	Brain atrophy: is treatment possible? A. Prat
10.45 – 11.00	Neuroprotection by blocking Sodium Channels K. Smith
11.00 – 11.15	Intravenous Immuglobulin F. Fazekas
11.15 – 11.30	Dextromethorphan/Quinidine for pseudobulbar affect in MS: Results of clinical trials and perspectives of future applications A. Miller
11.30 – 11.45	Discussion
12.00 – 14.00	Lunch

Afternoon session

Immunosuppression: promises and failures

Chairmen:	F. Fazekas and J. Palace
14.00 – 14.15	Immunosuppression: promises and failures J. Oger
14.15 – 14.30	Minocycline V.Yong/ L.Metz
14.30 – 14.45	Bone marrow transplantation: does it stop MS progression? M. Freedman
14.45 – 15.00	Discussion
15.00 – 15.30	Coffee

Treatment Strategies

Chairmen:	O. Fernandez and G. Comi
15.30 – 15.45	Gene expression profiling to monitor disease evolution and treatment effects C. Stürzebecher
15.45 – 16.00	Induction versus escalation H. Weiner
16.00 – 16.15	Combination treatments O. Fernandez
16.15 – 16.30	Stopping treatment L. Durelli
16.30 – 16.45	Discussion

Saturday November 19, 2005

Morning session

Treatment Strategies (continued)

Chairmen:	C. Confavreux and P. Soelberg Sørensen
8.30 – 8.45	Gene expression in MS – Towards patient-tailored treatment? A. Achiron
8.45 – 9.00	Duration of IFB treatment and risk of progression. Results of the Italian MSDN cohort analysis M. Trojano
9.00 – 9.15	Early treatment: rationale and proof G. Comi
9.15 – 9.30	Discussion
9.30 – 10.00	Coffee

Patient monitoring: individual patient care

Chairmen:	R. Gonsette and H. Weiner
10.00 – 10.15	Step-wise treatment design in individual patient care P. Rieckmann
10.15 – 10.30	The urgent need to optimise individual treatment strategies C. Confavreux
10.30 – 10.45	Shared decision making C. Heesen
10.45 – 11.00	How to measure outcome in individual patient care? Traditional outcomes and clues from the Nice Declaration M. Amato
11.00 – 11.15	Discussion
11.15 – 12.00	European Charcot Foundation Awards Presentation
12.00 – 14.00	Lunch

Afternoon session

Patient monitoring: individual patient care (continued)

Chairmen:	J. Palace and G. Comi
14.00 – 14.15	The place of MRI in individual patient monitoring D. Arnold
14.15 – 14.30	The gap between efficacy of drugs and effectiveness of treatments P. Soelberg Sørensen
14.30 – 14.45	What to do when we passed the zone of evidence? D. Brassat
14.45 – 15.45	<u>Round table discussion</u>

Rules for individual patient care in MS.

Lisbon declaration

	J. Palace - Chair
	A. Achiron, M. Amato, G. Comi, G. Edan, F. Fazekas, M. Trojano
15.45	Closure of Symposium O.R. Hommes